Medicare Price-Negotiation List Expanded—See If Your Drug Made It
Medicare's drug price negotiation program has entered its second phase, adding 15 medications to the list of treatments subject to price negotiations. This expansion follows the initial round that targeted ten high-cost drugs for 2026, and represents a significant step in reducing prescription costs for millions of beneficiaries enrolled in Medicare Part D plans.
The newly selected medications span critical therapeutic areas including heart disease, cancer, blood disorders, and autoimmune conditions. These treatments were chosen based on their high spending levels under Medicare Part D and the absence of generic or biosimilar alternatives. The negotiated prices will take effect on January 1, 2027, and are expected to generate substantial savings for both beneficiaries and the Medicare program.
Understanding the Selection Process
The Centers for Medicare & Medicaid Services (CMS) follows a structured approach to identify drugs eligible for price negotiation under the Inflation Reduction Act. Each year, medications are evaluated based on total Medicare Part D spending over a specified period, with priority given to treatments lacking generic competition and those representing significant financial burden to the program.
For the 2027 negotiation cycle, CMS analyzed spending data from June 2022 through May 2023, identifying the top 50 drugs by total expenditure. From this pool, medications were excluded if they had been on the market for fewer than seven years for small-molecule drugs or eleven years for biologics. The final selection of 15 drugs represents those with the highest financial impact and greatest potential for cost reduction through negotiation.
Medications Added to the 2027 List
The expanded negotiation list includes treatments that millions of Medicare beneficiaries rely on for managing chronic and serious conditions. Among the selections are medications for cardiovascular disease, including treatments for heart failure and blood clot prevention. Cancer therapies targeting various malignancies also feature prominently, reflecting the high cost of oncology care within the Medicare population.
Additional medications address autoimmune disorders such as rheumatoid arthritis and Crohn's disease, conditions requiring long-term treatment with expensive biologic drugs. Blood disorder treatments, including therapies for certain types of anemia and clotting disorders, round out the list. The specific brand names and therapeutic uses can be found on the Medicare Drug Price Negotiation Program page, where CMS maintains updated information on all selected medications.
How Negotiated Prices Reduce Costs
The negotiation process involves detailed discussions between CMS and pharmaceutical manufacturers, with the goal of establishing maximum fair prices that balance affordability for beneficiaries with incentives for continued innovation. Unlike traditional rebate structures, negotiated prices represent binding agreements that directly limit what Medicare Part D plans pay for covered medications.
These reduced prices translate to lower out-of-pocket costs for beneficiaries in multiple ways. First, the negotiated prices lower the list price that serves as the basis for calculating coinsurance amounts during the initial coverage phase. Second, they reduce costs during the coverage gap, commonly known as the donut hole, where beneficiaries historically faced higher cost-sharing. Finally, the savings help beneficiaries reach catastrophic coverage thresholds more slowly, potentially avoiding the highest out-of-pocket spending tiers altogether.
Early projections suggest that the 15 newly selected drugs could generate billions in combined savings over the first year of implementation. Individual beneficiary savings will vary based on specific medications used, plan design, and whether they qualify for additional assistance programs.
Checking Your Medication Status
Beneficiaries who take prescription medications regularly should verify whether any of their treatments appear on the expanded negotiation list. The most reliable method involves visiting the official CMS website and reviewing the published list of selected drugs, which includes both brand names and generic equivalents where applicable.
Medicare beneficiaries can also contact their Part D plan provider directly to inquire about specific medications and how negotiated pricing will affect their coverage beginning in 2027. Plan representatives can provide personalized information about formulary placement, tier status, and estimated cost-sharing under the new pricing structure.
For those who prefer telephone assistance, calling 1-800-MEDICARE provides access to trained counselors who can explain the negotiation program and help identify whether specific medications are included. State Health Insurance Assistance Programs also offer free counseling services to help beneficiaries understand their coverage options and potential savings.
Implementation Timeline and Expectations
The negotiation process for the 2027 drug list follows a structured timeline established by federal regulations. Pharmaceutical manufacturers had until October 2024 to submit required data to CMS, including information on research and development costs, manufacturing expenses, and existing pricing arrangements with other payers.
CMS will publish the negotiated maximum fair prices by August 1, 2026, giving Medicare Part D plans sufficient time to incorporate the new pricing into their 2027 benefit designs. Beneficiaries will see the impact when they select or renew their Part D coverage during the fall 2026 open enrollment period, which runs from October 15 through December 7.
Plans must reflect the negotiated prices in their formularies and provide clear information about cost-sharing amounts for affected medications. This transparency allows beneficiaries to compare plans effectively and choose coverage that best meets their medication needs while maximizing savings from negotiated pricing.
Beyond 2027: Future Expansion
The Medicare drug price negotiation program will continue to expand in subsequent years, adding more medications to the list of negotiated treatments. By 2029, the program is scheduled to include up to 20 drugs annually, covering an increasingly broad range of therapeutic categories and reaching more beneficiaries.
This phased approach allows CMS to refine the negotiation process while pharmaceutical manufacturers adjust to the new pricing environment. Over time, the cumulative impact of negotiated prices is expected to significantly reduce Medicare spending on prescription drugs while improving affordability for beneficiaries who depend on expensive medications to manage chronic conditions.
Future selections will continue to prioritize high-spending drugs without generic competition, ensuring that the program targets medications where negotiation can deliver the greatest financial benefit. Beneficiaries should stay informed about annual additions to the negotiation list and review their Part D coverage each year to take full advantage of available savings.
Additional Assistance Programs
Beyond negotiated drug prices, Medicare beneficiaries may qualify for additional programs that further reduce prescription costs. The Extra Help program, also known as the Low-Income Subsidy, provides assistance with Part D premiums, deductibles, and cost-sharing for eligible individuals with limited income and resources.
State Pharmaceutical Assistance Programs operate in many states to supplement Medicare coverage, often covering medications or cost-sharing amounts not fully addressed by Part D plans. Eligibility requirements and benefits vary by state, so beneficiaries should research programs available in their area through their State Health Insurance Assistance Program or local Area Agency on Aging.
Manufacturer patient assistance programs may also provide support for brand-name medications, including some of those on the negotiation list. These programs typically require application and documentation of financial need, but can offer significant savings for eligible beneficiaries who meet income thresholds.